vs
Side-by-side financial comparison of ATLANTIC AMERICAN CORP (AAME) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
Xeris Biopharma Holdings, Inc. is the larger business by last-quarter revenue ($85.8M vs $53.8M, roughly 1.6× ATLANTIC AMERICAN CORP). Xeris Biopharma Holdings, Inc. runs the higher net margin — 12.9% vs 1.1%, a 11.8% gap on every dollar of revenue. On growth, Xeris Biopharma Holdings, Inc. posted the faster year-over-year revenue change (42.8% vs 20.8%). Over the past eight quarters, Xeris Biopharma Holdings, Inc.'s revenue compounded faster (45.3% CAGR vs 7.2%).
The Atlantic Telegraph Company was a company formed on 6 November 1856 to undertake and exploit a commercial telegraph cable across the Atlantic Ocean, the first such telecommunications link.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
AAME vs XERS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $53.8M | $85.8M |
| Net Profit | $577.0K | $11.1M |
| Gross Margin | — | — |
| Operating Margin | 1.4% | 19.5% |
| Net Margin | 1.1% | 12.9% |
| Revenue YoY | 20.8% | 42.8% |
| Net Profit YoY | 128.9% | 316.7% |
| EPS (diluted) | $0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $85.8M | ||
| Q3 25 | $53.8M | $74.4M | ||
| Q2 25 | $55.3M | $71.5M | ||
| Q1 25 | $50.1M | $60.1M | ||
| Q4 24 | $49.0M | $60.1M | ||
| Q3 24 | $44.5M | $54.3M | ||
| Q2 24 | $47.7M | $48.1M | ||
| Q1 24 | $47.0M | $40.6M |
| Q4 25 | — | $11.1M | ||
| Q3 25 | $577.0K | $621.0K | ||
| Q2 25 | $3.3M | $-1.9M | ||
| Q1 25 | $802.0K | $-9.2M | ||
| Q4 24 | $412.0K | $-5.1M | ||
| Q3 24 | $-2.0M | $-15.7M | ||
| Q2 24 | $-684.0K | $-15.0M | ||
| Q1 24 | $-2.0M | $-19.0M |
| Q4 25 | — | 19.5% | ||
| Q3 25 | 1.4% | 9.0% | ||
| Q2 25 | 7.6% | 6.3% | ||
| Q1 25 | 2.1% | -5.1% | ||
| Q4 24 | 1.1% | 2.8% | ||
| Q3 24 | -5.5% | -23.8% | ||
| Q2 24 | -1.8% | -17.0% | ||
| Q1 24 | -5.3% | -35.1% |
| Q4 25 | — | 12.9% | ||
| Q3 25 | 1.1% | 0.8% | ||
| Q2 25 | 6.0% | -2.7% | ||
| Q1 25 | 1.6% | -15.3% | ||
| Q4 24 | 0.8% | -8.5% | ||
| Q3 24 | -4.5% | -29.0% | ||
| Q2 24 | -1.4% | -31.2% | ||
| Q1 24 | -4.3% | -46.7% |
| Q4 25 | — | $0.07 | ||
| Q3 25 | $0.02 | $0.00 | ||
| Q2 25 | $0.15 | $-0.01 | ||
| Q1 25 | $0.03 | $-0.06 | ||
| Q4 24 | $0.01 | $-0.02 | ||
| Q3 24 | $-0.10 | $-0.11 | ||
| Q2 24 | $-0.04 | $-0.10 | ||
| Q1 24 | $-0.10 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.4M | $111.0M |
| Total DebtLower is stronger | — | $220.3M |
| Stockholders' EquityBook value | $109.5M | $13.7M |
| Total Assets | $430.9M | $383.5M |
| Debt / EquityLower = less leverage | — | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $111.0M | ||
| Q3 25 | $34.4M | $91.6M | ||
| Q2 25 | $46.4M | $59.3M | ||
| Q1 25 | $35.9M | $58.4M | ||
| Q4 24 | $35.6M | $71.6M | ||
| Q3 24 | $23.0M | $69.4M | ||
| Q2 24 | $21.2M | $77.6M | ||
| Q1 24 | $21.2M | $87.4M |
| Q4 25 | — | $220.3M | ||
| Q3 25 | — | $219.5M | ||
| Q2 25 | — | $218.6M | ||
| Q1 25 | — | $229.8M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $216.2M | ||
| Q2 24 | — | $230.5M | ||
| Q1 24 | — | $229.7M |
| Q4 25 | — | $13.7M | ||
| Q3 25 | $109.5M | $-861.0K | ||
| Q2 25 | $106.2M | $-19.3M | ||
| Q1 25 | $102.4M | $-35.1M | ||
| Q4 24 | $99.6M | $-29.6M | ||
| Q3 24 | $105.8M | $-28.3M | ||
| Q2 24 | $100.7M | $-19.3M | ||
| Q1 24 | $102.8M | $-9.2M |
| Q4 25 | — | $383.5M | ||
| Q3 25 | $430.9M | $370.2M | ||
| Q2 25 | $429.3M | $334.7M | ||
| Q1 25 | $388.4M | $315.5M | ||
| Q4 24 | $393.4M | $323.1M | ||
| Q3 24 | $387.0M | $321.1M | ||
| Q2 24 | $386.0M | $331.7M | ||
| Q1 24 | $365.8M | $336.6M |
| Q4 25 | — | 16.10× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $20.0M |
| Free Cash FlowOCF − Capex | $6.6M | — |
| FCF MarginFCF / Revenue | 12.3% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 11.51× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | $19.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.0M | ||
| Q3 25 | $6.6M | $18.4M | ||
| Q2 25 | $9.3M | $182.0K | ||
| Q1 25 | $-722.0K | $-10.0M | ||
| Q4 24 | $4.8M | $2.0M | ||
| Q3 24 | $90.0K | $-8.3M | ||
| Q2 24 | $416.0K | $-10.3M | ||
| Q1 24 | $-5.3M | $-20.3M |
| Q4 25 | — | — | ||
| Q3 25 | $6.6M | — | ||
| Q2 25 | $9.1M | — | ||
| Q1 25 | $-986.0K | — | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | $58.0K | — | ||
| Q2 24 | $361.0K | — | ||
| Q1 24 | $-5.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | 12.3% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 9.3% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | -11.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 1.81× | ||
| Q3 25 | 11.51× | 29.68× | ||
| Q2 25 | 2.80× | — | ||
| Q1 25 | -0.90× | — | ||
| Q4 24 | 11.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAME
| Bankers Fidelity | $30.0M | 56% |
| American Southern | $23.7M | 44% |
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
